Arbutus: 2023 Corporate Objectives and Financial Update

 Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023

Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023

Strong financial position; cash runway into Q4 2024

https://www.biospace.com/article/releases/arbutus-announces-2023-corporate-objectives-and-provides-financial-update/